SCHEMBL4928056

SCHEMBL4928056

CC(=O)O[C@H](CBr)CC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
ALOX15 P16050 1/20 0.47
MMP12 P39900 1/20 0.45
CYP1A2 P05177 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HRH1 P35367 1/20 0.40
TSHR P16473 4/20 0.38
PGD P52209 1/20 0.36
MAPK1 P28482 2/20 0.33
SLC22A6 Q4U2R8 1/20 0.33
GMNN O75496 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923275 1.00 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL4923280 1.00 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL6153718 0.86 LMNA (0.67) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL7575659 0.84 LMNA (0.43) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL1116238 0.84
SCHEMBL4937252 0.81 SMN1; SMN2 (0.39) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL4937258 0.81 SMN1; SMN2 (0.39) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL4940791 0.81 SMN1; SMN2 (0.39) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL10414980 0.80 LMNA (0.60) LMNASMN1; SMN2ALOX15MMP12CYP1A2
SCHEMBL13229795 0.78 LMNA (0.58) LMNASMN1; SMN2ALOX15MMP12CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390825-B1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-24 US disclosed
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-19 US disclosed
US-20070265451-A1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2007-11-15 US disclosed
EP-1578723-A4 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF UNIV MICHIGAN STATE (US) 2006-11-02 EP disclosed
EP-1578723-A3 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF MICHIGAN STATE UNIVERSITY (US) 2005-10-20 EP disclosed
EP-1578723-A2 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF MICHIGAN STATE UNIVERSITY (US) 2005-09-28 EP disclosed
WO-2003106413-A2 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF MICHIGAN STATE UNIVERSITY (US) 2003-12-24 WO disclosed
US-6586616-B1 Cyanation and esterification of 3,4-epoxybutyric acid sodium salts to form chemical intermediates for antilipemic agents; by-product inhibition SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2003-07-01 US disclosed
EP-1149068-A4 A PROCESS FOR PREPARING (R)-4-CYANO-3-HYDROXYBUTYRIC ACID ESTER SAMSUNG FINE CHEMICALS CO LTD (KR) 2003-01-02 EP disclosed
WO-2002096915-A1 PROCESS FOR PRODUCING OPTICALLY PURE Δ - HYDROXY-Β -KETOESTER DERIVATIVES SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2002-12-05 WO disclosed
EP-1109797-B1 PROCESS FOR MANUFACTURING AN OPTICALLY ACTIVE (S)-3,4-EPOXYBUTYRIC ACID SALT SAMSUNG FINE CHEMICALS CO LTD (KR) 2002-03-27 EP disclosed
EP-1149068-A1 A PROCESS FOR PREPARING (R)-4-CYANO-3-HYDROXYBUTYRIC ACID ESTER Samsung Fine Chemicals Co., Ltd. (KR) 2001-10-31 EP disclosed
US-6284902-B1 Process for manufacturing an optically active (S)-3,4-epoxybutyric acid salt SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2001-09-04 US disclosed
EP-1109797-A1 PROCESS FOR MANUFACTURING AN OPTICALLY ACTIVE (S)-3,4-EPOXYBUTYRIC ACID SALT Samsung Fine Chemicals Co., Ltd. (KR) 2001-06-27 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000046186-A1 A PROCESS FOR PREPARING (R)-4-CYANO-3-HYDROXYBUTYRIC ACID ESTER SAMSUNG FINE CHEMICALS CO., LTD (KR) 2000-08-10 WO disclosed
WO-2000005227-A1 PROCESS FOR MANUFACTURING AN OPTICALLY ACTIVE (S)-3,4-EPOXYBUTYRIC ACID SALT SAMSUNG FINE CHEMICALS CO., LTD. (KR) 2000-02-03 WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265451-A1 Process for the preparation of oxazolidinones and method of use thereof OXA1L, OTC, ODC1 LMNA 2973/4885SMN1; SMN2 2201/4885ALOX15 1542/4885
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF OXA1L, OGFOD1, CYP51A1 LMNA 2631/4885SMN1; SMN2 1713/4885ALOX15 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.